Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to $4.0 million.

  • Enanta Pharmaceuticals' Share-based Compensation fell 4773.26% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.6 million, marking a year-over-year decrease of 3071.47%. This contributed to the annual value of $18.6 million for FY2025, which is 3071.47% down from last year.
  • As of Q3 2025, Enanta Pharmaceuticals' Share-based Compensation stood at $4.0 million, which was down 4773.26% from $4.2 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' 5-year Share-based Compensation high stood at $8.1 million for Q4 2023, and its period low was $4.0 million during Q3 2025.
  • In the last 5 years, Enanta Pharmaceuticals' Share-based Compensation had a median value of $6.1 million in 2021 and averaged $6.1 million.
  • In the last 5 years, Enanta Pharmaceuticals' Share-based Compensation surged by 3886.76% in 2022 and then crashed by 4773.26% in 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Share-based Compensation (Quarter) stood at $6.1 million in 2021, then increased by 17.77% to $7.1 million in 2022, then grew by 13.45% to $8.1 million in 2023, then plummeted by 30.04% to $5.7 million in 2024, then decreased by 28.8% to $4.0 million in 2025.
  • Its Share-based Compensation stands at $4.0 million for Q3 2025, versus $4.2 million for Q2 2025 and $4.7 million for Q1 2025.